Tradestie Institutional Equity Comparison Engine
CRBP vs ENTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (3โ0 Pillars ยท 5โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CRBP trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus ENTX at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, CRBP sits in BREAKDOWN (66th %ile IV; Dealer Gamma Walls on Pro) against ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CRBP N/M vs ENTX N/M Fwd P/E
Growth & Margin Winner
ENTX
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs -100.0%
Momentum & Technical Winner
ENTX
1Y -69.5% vs +10.2% ยท 52W Pos 6% vs 64%
Options & Structure Winner
ENTX
BREAKDOWN (66th %ile IV) vs CONSOLIDATION (32nd %ile IV)
CRBP
NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap
$69.9M
1M Return
-25.33%
1Y Return
-69.51%
Forward P/E
N/M
Unified AI Score
45.0 / 100
HOLD
Tech 43.0
Fund 54.0
Flow 69.0
Mom 64.0
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.02
-2.89% 1D
Market Cap
$541.6M
1M Return
+12.69%
1Y Return
+10.22%
Forward P/E
N/M
Unified AI Score
53.9 / 100
HOLD
Tech 37.0
Fund 54.0
Flow 72.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CRBP -69.51%
ENTX +10.22%
Spread: +79.73 pp (ENTX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRBP Revenue | ENTX Revenue | CRBP Op. Margin | ENTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2017 | $0M | N/A | -1334.4% | N/A | CRBP |
| FY2018 | $0M | N/A | -1176.8% | N/A | CRBP |
| FY2019 | $40M | N/A | -213.3% | N/A | CRBP |
| FY2020 | $0M | $0M | -3119.2% | -3059.7% | ENTX |
| FY2021 | $0M | $0M | -6350.1% | -2139.6% | ENTX |
| FY2022 | N/A | $0M | N/A | -9714.2% | ENTX |
| FY2024 | N/A | $0M | N/A | -5295.6% | ENTX |
| FY2025 | N/A | $0M | N/A | -27450.0% | ENTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRBP | ENTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $69.9M | $541.6M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | -100.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -131.5% | -20.3% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 6% ($3โ$13) | 64% ($1โ$4) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | 1.93ฮฒ ยท 121% Vol | 1.07ฮฒ ยท 46% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 45.0 / 100 (HOLD) | 53.9 / 100 (HOLD) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CRBP vs ENTX Buy Guide
CRBP
BREAKDOWN
58d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
66th %ile
IV Regime
Elevated (60thโ80th %ile)
ENTX
CONSOLIDATION
79d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
32nd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CRBP nor ENTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.